Novel immune-based treatment strategies for chronic lymphocytic leukemia - PubMed (original) (raw)

Review

. 2005 Sep 10;23(26):6325-32.

doi: 10.1200/JCO.2005.05.008.

Affiliations

• PMID: 16155015
• DOI: 10.1200/JCO.2005.05.008

Review

Novel immune-based treatment strategies for chronic lymphocytic leukemia

William G Wierda et al. J Clin Oncol. 2005.

Abstract

Immune-based treatments represent a new group of therapeutic strategies for patients with cancer, including chronic lymphocytic leukemia (CLL), that employ immune effector mechanisms. Among these strategies is passive immunotherapy with monoclonal antibody, alone or in combination with chemotherapy. Active immunotherapy strategies currently under development include vaccines, administration of expanded and activated T cells, and allogeneic stem cell transplantation. These immune-based strategies represent new treatments with potentially complementary mechanisms of action to standard therapies and signify major advances in treatments for patients with CLL.

PubMed Disclaimer

Similar articles

• Treatment options for newly diagnosed patients with chronic lymphocytic leukemia.
  Erba HP. Erba HP. Curr Hematol Rep. 2004 Jan;3(1):47-53. Curr Hematol Rep. 2004. PMID: 14695850 Review.
• Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
  Robak T. Robak T. Transfus Apher Sci. 2005 Feb;32(1):33-44. doi: 10.1016/j.transci.2004.10.004. Transfus Apher Sci. 2005. PMID: 15737872 Review.
• Chemoimmunotherapy of chronic lymphocytic leukemia.
  Tam CS, Keating MJ. Tam CS, et al. Best Pract Res Clin Haematol. 2007 Sep;20(3):479-98. doi: 10.1016/j.beha.2007.02.004. Best Pract Res Clin Haematol. 2007. PMID: 17707835 Review.
• The role of stem cell transplantation in the management of chronic lymphocytic leukaemia.
  Tam CS, Khouri I. Tam CS, et al. Hematol Oncol. 2009 Jun;27(2):53-60. doi: 10.1002/hon.884. Hematol Oncol. 2009. PMID: 19358149 Review.
• Alemtuzumab in chronic lymphocytic leukemia.
  James DF, Kipps TJ. James DF, et al. Future Oncol. 2007 Feb;3(1):29-42. doi: 10.2217/14796694.3.1.29. Future Oncol. 2007. PMID: 17280499 Review.

Cited by

• Immunosuppressive drug therapy for preventing rejection following lung transplantation in cystic fibrosis.
  Saldanha IJ, Akinyede O, Robinson KA. Saldanha IJ, et al. Cochrane Database Syst Rev. 2018 Jun 18;6(6):CD009421. doi: 10.1002/14651858.CD009421.pub4. Cochrane Database Syst Rev. 2018. PMID: 29921013 Free PMC article. Review.
• GIFT4 fusokine converts leukemic B cells into immune helper cells.
  Deng J, Pennati A, Cohen JB, Wu Y, Ng S, Wu JH, Flowers CR, Galipeau J. Deng J, et al. J Transl Med. 2016 Apr 27;14(1):106. doi: 10.1186/s12967-016-0865-1. J Transl Med. 2016. PMID: 27118475 Free PMC article.
• Alemtuzumab for patients with chronic lymphocytic leukaemia.
  Skoetz N, Bauer K, Elter T, Monsef I, Roloff V, Hallek M, Engert A. Skoetz N, et al. Cochrane Database Syst Rev. 2012 Feb 15;2012(2):CD008078. doi: 10.1002/14651858.CD008078.pub2. Cochrane Database Syst Rev. 2012. PMID: 22336834 Free PMC article. Review.
• Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab.
  Treon SP, Soumerai JD, Hunter ZR, Patterson CJ, Ioakimidis L, Kahl B, Boxer M. Treon SP, et al. Blood. 2011 Jul 14;118(2):276-81. doi: 10.1182/blood-2011-02-338558. Epub 2011 May 12. Blood. 2011. PMID: 21566092 Free PMC article. Clinical Trial.
• Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia.
  Wierda WG, Kipps TJ, Keating MJ, Brown JR, Gribben JG, Browning M, Rassenti LZ, Greaves AW, Neuberg D, O'Brien SM; CLL Research Consortium. Wierda WG, et al. Cancer. 2011 Jan 1;117(1):116-24. doi: 10.1002/cncr.25379. Epub 2010 Aug 30. Cancer. 2011. PMID: 20806349 Free PMC article. Clinical Trial.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.